Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD

Divya Tiwari, MD, John Horan, Amelia Langston, MD, Muna Qayed, M.D., M.Sc., Jennifer Carr, Heather Renfroe, Couture Cynthia, Hanna J. Khoury, MD, Robertson Jennifer, R. Donald Harvey, PharmD, Aneesh Mehta, Edmund K. Waller, MD, PhD, Leslie S. Kean, MD, PhD

Blood (2012) 120 (21): 741.

https://doi.org/10.1182/blood.V120.21.741.741

Published: 2012

Journal Articles

CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial,

Leslie S. Kean, MD, PhD, Amelia Langston, MD, Muna Qayad, MD, H. Jean Khoury, MD, FACP, Divya Tiwari, MD, Cynthia Couture, Heather Renfroe, Sharon Sen, Jennifer Robertson, PhD, Edmund K Waller, MD PhD, John T. Horan

Blood (2011) 118 (21): 4078.

https://doi.org/10.1182/blood.V118.21.4078.4078

Published: 2011

Journal Articles

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

R. Donald Harvey, PharmD, Sagar Lonial, MD, Heather Renfroe, Rajni Sinha, MD, MRCP, Christopher R Flowers, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, FACP, Amelia Langston, MD, Edmund K Waller, MD PhD, Jonathan L. Kaufman, MD

Blood (2011) 118 (21): 2988.

https://doi.org/10.1182/blood.V118.21.2988.2988

Published: 2011

Journal Articles

Cost-Effectiveness Analysis of a “Just-In-Time” Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant

Jie Li, Ellie Hamilton, Louette Vaughn, Michael Graiser, Heather Renfroe, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Christopher R Flowers, MD, MS, Mary Jo Lechowicz, MD, Amelia Langston, MD, Darlene Anderson, Edmund Waller, MD, PhD

Blood (2010) 116 (21): 2246.

https://doi.org/10.1182/blood.V116.21.2246.2246

Published: 2010

Journal Articles

A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.

Heather Renfroe, Edmund K. Waller, MD, PhD, Mike Arnold, Louette Vaughn, R. Donald Harvey, PharmD, Ellie Hamilton, Sagar Lonial, MD, H. Jean Khoury, MD, Jonathan L. Kaufman, MD, Mary Jo Lechowicz, MD

Blood (2009) 114 (22): 4230.

https://doi.org/10.1182/blood.V114.22.4230.4230

Published: 2009

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Claire Torre, Amelia Langston, Mary J. Lechowicz, Christopher Flowers, Stephanie McMillan, Heather Renfroe, Leonard T Heffner, Edmund K Waller

Blood (2008) 112 (11): 3332.

https://doi.org/10.1182/blood.V112.11.3332.3332

Published: 2008

NARROW

A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD

CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial,

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

Cost-Effectiveness Analysis of a “Just-In-Time” Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant

A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Email alerts

ASH Publications

American Society of Hematology

A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD

CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial,

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

Cost-Effectiveness Analysis of a “Just-In-Time” Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant

A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only